Aptamer Group Announces Agreement with AstraZeneca to Explore Next-Generation Drug Delivery Devices

7th January 2019
Aptamer Group today announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney. The two-year agreement will give AstraZeneca use of Aptamer Group’s proprietary technology to explore the feasibility of developing the next generation of drug delivery vehicles, called Aptamer Drug Conjugates (ApDCs).

Aptamers […]

Aptamer Group December 2018

19th December 2018
This month:

Aptamer Group data on selective cell based biomarker aptamers
The year in review, from new product launches to company accolades
Interesting applications in international diagnostics and small molecule lateral flow assays

Novel Solutions – Biomarkers 
Aptamers specific to the same cell type at different stages within a disease cycle

No biomarker abundance restriction
Whole […]

Aptamer Group November 2018

29th November 2018.
This month:

Aptamer Group data on selective bind and elution reusability of aptamer  purification columns
Small molecule analysis webinar with Pall ForteBio BLI platform
Our CEO Today United Kingdom award
Interesting applications in antibiotic biosensors and ELISA antibody/aptamer pairs

Novel Solutions – Purification 
Reproducibility of aptamers that bind and release under defined conditions

Less expensive
Gentle […]

CEO Today Magazine Awards – Winners

3rd December 2018
Aptamer Group is proud to receive the CEO Today Magazine United Kingdom Awards for distinguished performance by our CEO and Founder Arron Tolley.

The award recognises, identifies and honours the most respected companies and their C-level executives operating within the United Kingdom today. Researchers at CEO Today determine the eligibility of the CEO/Executive based […]

Aptamer Group Secures $2.2m Series A Investment

Arron Tolley, CEO – I’m delighted to announce that Aptamer Group Ltd, has recently closed its Series A investment round; attracting international interest and securing $2.2m of funding from overseas investors, to support its pioneering aptamer development pipeline.

Aptamer technology is rapidly evolving and will continue to have a significant impact on the life sciences market […]

Aptamer Group visits the University of Manchester

A guest seminar by Dr David Bunka
In October Dr David Bunka (CTO, Aptamer Group) visited the University of Manchester to deliver a seminar introducing aptamers and the variety of applications where they can be used. This seminar enabled members within the university to find out how aptamers can be used in their research. Having designed […]

Venturefest Yorkshire, 2016

10 November 2016

We are thrilled to announce that our CTO Dr David Bunka has been invited to speak at our local Venture Fest here in Yorkshire. The conference will be held on Wednesday 16th November 2016 at York Racecourse.

Organised by Made It York, Venturefest Yorkshire is a one day festival with a clear remit to […]

The New Age of Aptamer Based Biosensors

29 July 2016

There is an increasing interest in developing new biosensors for diagnostics and basic research applications. In light of the emerging aptamer technology, aptamer-based biosensors (Aptasensors) are expected to be one of the most promising devices in bioassay related applications (Han, Liang, and Zhou., 2010). However given this noted promise, the application of aptamer […]

CLINAM European Foundation for Clinical Nanomedicine Conference

06 July 2016

We were thrilled to be invited by Dr Beat Loeffler to represent our aptamer technology at CLINAM, European Foundation for Clinical Nanomedicine 2016.

In the previous eight years, CLINAM summit grew to the largest in its field with 12 presenting Noble Laureates and more than 500 participants from academia, industry, regulatory authorities and policy […]